Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 7, 2015

Primary Completion Date

June 26, 2017

Study Completion Date

December 25, 2020

Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
DRUG

Talimogene Laherparepvec

The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.

Trial Locations (42)

1000

Research Site, Brussels

1085

Research Site, Budapest

1090

Research Site, Vienna

1122

Research Site, Budapest

1200

Research Site, Brussels

4000

Research Site, Liège

4032

Research Site, Debrecen

5020

Research Site, Salzburg

6720

Research Site, Szeged

7632

Research Site, Pécs

11527

Research Site, Athens

13385

Research Site, Marseille

18547

Research Site, Athens

20014

Research Site, Donostia / San Sebastian

20141

Research Site, Milan

24127

Research Site, Bergamo

26504

Research Site, Pátrai

28009

Research Site, Madrid

28041

Research Site, Madrid

30625

Research Site, Hanover

44093

Research Site, Nantes

45147

Research Site, Essen

46014

Research Site, Valencia

53100

Research Site, Siena

54622

Research Site, Thessaloniki

60590

Research Site, Frankfurt am Main

69120

Research Site, Heidelberg

71110

Research Site, Heraklion - Crete

75010

Research Site, Paris

84112

Research Site, Salt Lake City

86021

Research Site, Poitiers

92100

Research Site, Boulogne-Billancourt

115478

Research Site, Moscow

197758

Research Site, Saint Petersburg

1081 HV

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

62-500

Research Site, Konin

02-781

Research Site, Warsaw

08916

Research Site, Badalona

08036

Research Site, Barcelona

SE1 9RT

Research Site, London

CH63 4JY

Research Site, Metropolitan Borough of Wirral

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY